Selected outcome
Before 2028
91%
Before 2028 · 91%
Stored quote · checking the venue
- Scheduled end
- Jun 30, 2027 ET
- Resolution source
- U.S. Food and Drug Administration. (opens in a new tab)
Price
Loading price history.
Markets
- Before July 2027
When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema?
89%
Open · ~$0 24h · ~$4,094 vol
Bid 87¢ · Ask 91¢
- Before October 2027
When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema?
91%
Open · ~$0 24h · ~$1,000 vol
Bid 89¢ · Ask 93¢
- Before 2028
When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema?
91%
Open · ~$0 24h · ~$629 vol
Bid 89¢ · Ask 92¢
Event statistics
How this resolves
- Scheduled end
- Jun 30, 2027 ET
- Resolution source
- Trading
- Closed
- In review
- Resolved
Rules text
If the FDA approves Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema for marketing before Jan 1, 2028, then the market resolves to Yes.